

UNITED STATES DEPARTMENT OF COMMERCE United States Pat int and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATT	ATTORNEY DOCKET NO.	
09/765,	491 01/18/01	ARBISER		J	EU 98055 CO	
- 023579	9 HM22/0727 ⁻		\neg		EXAMINER	
	PABST & KNIGHT LLP			KIM,J		
	000, ONE ATLAM	NTIC CENTER		ART UNIT	PAPER NUMBER	
1201 WE	ST PEACHTREE (STREET, N.E.		1617	3	
ATLANTA	GA 30309-340	,		DATE MAILED:	07/27/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

			_
	Application No.	Applicant(s)	
	09/765,491	ARBISER, JACK L.	
Office Action Summary	Examiner	Art Unit	_
	Jennifer M Kim	1617	_
The MAILING DATE of this communication appeariod for Reply	ppears on the cover sheet	with the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statu - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	136(a). In no event, however, may ply within the statutory minimum of d will apply and will expire SIX (6) N tte, cause the application to become	a reply be timely filed thirty (30) days will be considered timely. ONTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).	
1) Responsive to communication(s) filed on 18	3 January 2001 .		
2a) ☐ This action is FINAL . 2b) ☐ T	his action is non-final.		
3) Since this application is in condition for allow closed in accordance with the practice unde			
Disposition of Claims			
4)⊠ Claim(s) 4-6 and 10-17 is/are pending in the	application.		
4a) Of the above claim(s) is/are withdra	awn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) <u>4-6, 10-17</u> are subject to restriction	and/or election requireme	ent.	
Application Papers			
9)☐ The specification is objected to by the Examin	ner.		
10) The drawing(s) filed on is/are: a) acc	epted or b)⊡ objected to b	y the Examiner.	
Applicant may not request that any objection to t			
11) The proposed drawing correction filed on		disapproved by the Examiner.	
If approved, corrected drawings are required in r	•		
12) The oath or declaration is objected to by the E	xamıner.		
Priority under 35 U.S.C. §§ 119 and 120			
13) Acknowledgment is made of a claim for foreign	gn priority under 35 U.S.	C. § 119(a)-(d) or (f).	
a) ☐ All b) ☐ Some * c) ☐ None of:			
1. ☐ Certified copies of the priority documer			
2. Certified copies of the priority documer			
 3. Copies of the certified copies of the pri application from the International B * See the attached detailed Office action for a lis 	Bureau (PCT Rule 17.2(a)).	
14) Acknowledgment is made of a claim for domes	stic priority under 35 U.S.	C. § 119(e) (to a provisional application).	
a) The translation of the foreign language p			
Attachment(s)			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice	ew Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)	
S Patent and Trademark Office			

Application/Control Number: 09/765,491

Art Unit: 1617

Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 4-6, 10-12, and 17 drawn to a method for inhibiting skin disorders comprising an angiogenesis inhibitor.
 - Claims 13-16, drawn to a pharmaceutical composition comprising a curcumin in combination with a pharmaceutically acceptable carrier.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions Group I and Group II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that

Application/Control Number: 09/765,491

Page 3

Art Unit: 1617

product since the product has been used for treatment of bladder cancer.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Further restriction may be required.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is (703) 308-2232. The examiner can normally be reached on Monday through Friday from 9 AM. to 4 PM.

Application/Control Number: 09/765,491 Page 4

Art Unit: 1617

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, can be reached on (703) 308-4612. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Theodore J. Criares Primary Examiner Art Unit 1617

jmk July 25, 2001